Earnings call transcript: Auna misses Q2 2026 profit view as revenue beats

In Auna's second quarter 2026 earnings call, the company reported mixed results. Revenue of $1.24 billion surpassed Wall Street's estimate of $1.18 billion, while adjusted earnings per share came in at $0.50, falling short of the expected $0.8549. Growth remained robust in Mexico, Peru, and Colombia, but profitability suffered due to temporary margin pressure and billing penalties in Peru.

The stock experienced a sharp decline of 13.65% in premarket trading, closing at $4.68, near the stock's 52-week low. Despite the earnings miss, demand remained strong across Auna's healthcare network in Latin America, with Mexico being a key growth engine. Revenue in Mexico grew 4% year-over-year and 5% sequentially, with surgeries increasing 7% from the prior quarter.

Oncology services saw exceptional growth, with chemotherapy and radiotherapy volumes up 20% sequentially and oncology revenue up 110% year-over-year. Peru's revenue grew 8% year-over-year, driven by higher average ticket prices and membership expansion. Colombia delivered 13% revenue growth, with private payer revenue increasing 17% year-over-year.

Capacity utilization improved in all three markets, indicating healthy demand. Adjusted EBITDA declined 9% FX-neutral, as the company faced margin pressure in Mexico and Colombia and accepted billing penalties in Peru. Management noted that these issues should not affect the company's long-term growth outlook. Adjusted earnings of $0.50 per share missed analyst expectations by $0.3549 per share, a 41.5% shortfall.

Revenue beat exceeded expectations by $60 million, or 5.1%. The combination of revenue and earnings results suggests healthy demand but highlights cost pressures and margin challenges.